On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.

On July 16, 2024, 60 Degrees Pharmaceuticals, Inc. conducted its 2024 Annual Stockholders Meeting virtually. During the meeting, a quorum was established with approximately 51.86% of the outstanding voting shares represented. Five director nominees were elected to serve until the 2025 annual meeting. Additionally, stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available for issuance by 5 million. A reverse stock split of the common stock was also approved, with a ratio range from 1:5 to 1:12, to be determined by the Board of Directors. Modifications to the strike price of options for the CEO and CFO, as well as the issuance of options to a consultant, were approved to comply with Nasdaq Listing Rule 5635(c). Furthermore, RBSM LLP was ratified as the independent auditor for the fiscal year ending December 31, 2024. The meeting concluded with all proposals receiving the required majority approval from the shares represented.